Skopos Bio Raises $8.3 Million in Seed Funding
Skopos Bio, a company based in Queensland, Australia, has successfully raised $8.3 million in a seed funding round. The round was led by notable investors including Tenmile, Tin Alley Ventures, and Yosemite. Skopos Bio is focused on developing novel radiopharmaceuticals designed to target cancer cells more effectively than conventional treatments.
Founders and Leadership
The company was founded by a team of experts in the field: Professor Michael Hofman, Associate Professor Mohammad Haskali, and Associate Professor Luc Furic. These founders spun the company out of the Peter MacCallum Cancer Centre, leveraging their experience in advancing cancer diagnosis and treatment.
Use of Funds
The newly acquired funds will be directed towards further development and testing of Skopos Bio's innovative radioactive particles. These particles aim to deliver targeted radiation therapy to cancer cells, potentially covering a broader range of cancers than current treatments.
Innovative Approach to Cancer Treatment
Skopos Bio is working on radiopharmaceuticals that can reach cancer cells not accessible by traditional drugs. This approach is an extension of Professor Hofman's work on theranostic methods, which combine diagnostic imaging with targeted radiation therapy.
As Skopos Bio continues to develop its technology, the company aims to provide oncologists with more precise tools for targeting cancer cells, potentially improving outcomes for patients worldwide.